Predicting mortality in heart failure: BUN/creatinine ratio in MIMIC-III

Changsen Zhu1, Liyan Wu1, Yiyi Xu2

  • 1Department of Rehabilitation Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.

Insights

The blood urea nitrogen/creatinine ratio (BCR) shows a U-shaped association with mortality in heart failure patients. Higher BCR levels above 22 significantly increase mortality risk, while lower levels may offer a protective effect.

Area of Science:

  • Cardiology
  • Nephrology
  • Critical Care Medicine

Background:

  • Heart failure (HF) is a major cause of mortality worldwide.
  • The blood urea nitrogen/creatinine ratio (BCR) is a potential biomarker for HF outcomes.
  • Understanding the precise relationship between BCR and HF prognosis is crucial.

Purpose of the Study:

  • To investigate the impact of varying blood urea nitrogen/creatinine ratio (BCR) levels on mortality in heart failure patients.
  • To determine the prognostic value of BCR in critical care settings for heart failure.

Main Methods:

  • Retrospective cohort study of 1,475 heart failure patients from the MIMIC-III database.
  • Patients categorized into four quartiles based on admission BCR levels.
  • Survival outcomes analyzed using Kaplan-Meier and Cox proportional hazards models, with restricted cubic splines for nonlinear associations.

Main Results:

  • Increasing BCR levels correlated with longer hospital stays and decreased survival.
  • The highest BCR quartile exhibited significantly higher in-hospital (18.8%) and long-term (78.3%) mortality.
  • A U-shaped relationship was observed: no significant mortality risk below BCR 12.5, a potential protective effect between 12.5-22, and increased risk above 22.

Conclusions:

  • Admission BCR demonstrates a nonlinear association with mortality in heart failure.
  • BCR serves as a valuable prognostic tool for predicting outcomes in critically ill heart failure patients.
  • Specific BCR thresholds indicate varying risk levels, guiding clinical management.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
40
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
45
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
76
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
51
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
312